Shaanxi Mycotech Pharmaceutical Technology

Shaanxi Mycotech Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Xi'an, China, dedicated to the research and development of novel antifungal medications. The company focuses on addressing the limitations of current treatments for invasive fungal infections, particularly the toxicity issues associated with polyene antibiotics. Its lead program, MXP-009, is a proprietary derivative of Amphotericin B designed to offer broad-spectrum antifungal activity with a significantly improved safety profile, specifically targeting reduced renal toxicity. Mycotech's pipeline aims to provide critical therapeutic solutions for high-mortality conditions such as cryptococcal meningitis and systemic candidiasis. The company leverages advanced chemical synthesis and structural modification platforms to optimize existing classes of anti-infective agents. By improving the therapeutic index of gold-standard treatments, Mycotech seeks to reduce the clinical burden of life-threatening fungal diseases.